G01N2469/00

Triage biomarkers and uses therefor

Disclosed are methods, apparatus, kits and compositions for determining the absence of a systemic bacterial infection (sepsis) in patients, particularly ones presenting to hospital emergency departments (ED) as outpatients, by measurement of the host immune response using peripheral blood. The are methods, apparatus, kits and compositions can be used in mammals for diagnosing, making treatment decisions, determining the next procedure or diagnostic test, or management of patients suspected of having an infection, including those presenting with fever or other signs of systemic inflammation. More particularly, peripheral blood RNA and protein biomarkers are disclosed that are useful for distinguishing between the host immune response to bacteria compared to the host immune response to other causes of systemic inflammation including trauma, burns, autoimmune disease, asthma, anaphylaxis, arthritis, obesity and viral infections. As such, the biomarkers are useful for distinguishing bacterial-associated systemic inflammatory response syndrome from non-bacterial systemic inflammation to provide clinicians with strong negative predictive value (>95%) so that sepsis can be excluded as a diagnosis in patients presenting to ED with clinical signs of systemic inflammation.

ANTI-HERV-K ENVELOPE ANTIBODY AND USES THEREOF

The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or is therapy.

Target capture system

The invention generally relates to a system for isolating or separating a target from a sample. In certain aspects, processes performed by the target capture system include introducing a plurality of magnetic particles, in which a plurality of the particles include at least one binding moiety specific to a target, into a sample to form at least one target/particle complex and applying a magnetic field to isolate the magnetic particle/target complexes from the sample. The process starts at inputting a sample into the system and ends at delivering a capture target or nucleic acids of the target into a container for further analysis.

Methods for alleviating symptoms of sporadic amyotrophic lateral sclerosis by neutralizing a HERV-K envelope protein using an anti-HERV-K envelope protein antibody

The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.

METAL-ANTIBODY TAGGING AND PLASMA-BASED DETECTION

Various techniques for characterizing a target within a sample are described. An example method includes applying, to the sample, a recognition construct that includes a metal and a scaffold, wherein the scaffold is configured to bind to the target. Energy can be applied to the sample, wherein the applied energy is sufficient to transform at least some of the sample into a plasma. Electromagnetic radiation emitted by the plasma can be detected to provide an optical-spectrum signal of the sample.

Avian reovirus vaccines

The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses.

AVIAN REOVIRUS VACCINES
20200069788 · 2020-03-05 ·

The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast United States. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the S1 gene encoding the sigma C protein, and to vaccines that protect chickens from disease caused by such viruses.

METAL-ANTIBODY TAGGING AND PLASMA-BASED DETECTION

An apparatus and method for characterizing a target, e.g., microbial samples or biological toxins, includes labeling the target with a biomolecular recognition construct and measuring an atomic-spectra signal of the biomolecular recognition construct. The method can include heating the labeled target before measuring the atomic-spectra signal. The atomic-spectra signal can be measured by performing laser-induced breakdown spectroscopy. The atomic-spectra signal can be measured by performing spark induced breakdown spectroscopy. The biomolecular recognition construct can be prepared by tagging a biological scaffolding with a metal atom or ion. In an aspect in which the target includes a microbial sample, the biological scaffolding can include an antibody against epitopes present on bacterial surface, the antibody linked to a heavy metal. In an aspect in which the target includes a biological toxin, the biological scaffolding can include an antibody against the biological toxin linked to heavy metals.

ELECTROCHEMICAL IMMUNOSENSORS
20200025753 · 2020-01-23 ·

In a general aspect, an apparatus can include a first carbon nanotube array that is patterned to define a first electrode having a first plurality of electrode segments. The apparatus can also include a second carbon nanotube array that is patterned to define a second electrode having a second plurality of electrode segments. The second plurality of electrode segments can be interdigitated with the first plurality of electrode segments. The apparatus can further include a biorecognition agent disposed on a surface of the first electrode and disposed on a surface of the second electrode. The first plurality of electrode segments can each have a height-to-width aspect ratio of at least 1 to 1.

Metal-antibody tagging and plasma-based detection

A target within a sample can be characterized using an energy source configured to transform a metal in the sample into a plasma and an optical spectroscopic detector configured to detect electromagnetic radiation emitted by the plasma to provide an optical-spectrum signal. A processor can determine presence of the metal in the sample using the optical-spectrum signal. The target can include a microbe or biological toxin. A recognition construct comprising a metal and a scaffold can be applied to the sample. The scaffold can bind to the target. Energy can be applied to transform at least some of the sample into a plasma. Electromagnetic radiation emitted by the plasma can be detected to provide an optical-spectrum signal of the sample. A preparation subsystem can add the recognition construct to the sample and a washing subsystem can wash unbound recognition construct out of the sample.